Showing 561 - 580 results of 1,370 for search 'Akko~', query time: 0.92s Refine Results
  1. 561
  2. 562
  3. 563
  4. 564
  5. 565

    Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

    Published 2025-03-01
    “…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. …”
    Get full text
    Article
  6. 566
  7. 567
  8. 568
  9. 569

    A Case of Medullary Carcinoma of the Jejunum Combined with the Intestinal Lymphangiectasia Accompanied by the Malabsorption Syndrome by O. A. Lobanova, D. S. Trusova, M. A. Afonina, V. E. Varentsoy, D. D. Protsenko, N. V. Kretova, N. B. Serezhnikova, M. A. Peshkova, N. V. Zharkov, S. E. Kochetkova, Yu. Yu. Stepanova, Z. D. Shtanev, K. A. Vekhova, V. A. Yumasheva, A. O. Kolesnikova, M. Akan, M. O. Chanturiya, T. V. Serebrov, A. S. Tertychnyy, H. Guski, E. E. Rudenko, T. A. Demura, E. A. Kogan

    Published 2023-11-01
    “…The medullary carcinoma with positive expression of СD117, DOG1, EMA, PanCK, PDL-1, vimentin, mosaic non-intense expression of CA19-9, calretinin, CD10, CDX2, CEA, MUC-5AC, SATB2, and negative reaction to ALK, CD3, CD8, CD20, CD30, CD31, CD34, CD45, CD56, chromogranin, CK7, CK20, desmin. …”
    Get full text
    Article
  10. 570
  11. 571
  12. 572
  13. 573
  14. 574
  15. 575
  16. 576
  17. 577
  18. 578
  19. 579
  20. 580